Literature DB >> 11417969

Bone markers in the management of metastatic bone disease.

A Lipton1, L Costa, S M Ali, L M Demers.   

Abstract

Newer markers of bone formation and bone resorption are now available. Alone these new markers do not appear to be useful to diagnose metastatic bone disease. Several markers appear to be of prognostic importance and correlate with the extent of tumour in the skeleton. Serial monitoring of bone markers may be useful to monitor the efficacy of bisphosphonate and/or systemic therapy of both lytic and blastic bone metastases. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11417969     DOI： 10.1053/ctrv.2000.0212

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  13 in total

1.  Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.

Authors:  P Hadji; A Kauka; M Ziller; K Birkholz; M Baier; M Muth; M Bauer
Journal:  Osteoporos Int       Date:  2014-02-07       Impact factor: 4.507

2.  Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.

Authors:  Anne F Schott; William E Barlow; Catherine H Van Poznak; Daniel F Hayes; Carol M Moinpour; Danika L Lew; Philip A Dy; Evan T Keller; Jill M Keller; Gabriel N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  2016-07-30       Impact factor: 4.872

3.  N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases.

Authors:  Rieko Kaira; Haruyasu Murakami; Kyoichi Kaira; Toshiaki Takahashi; Asuka Tsuya; Yukiko Nakamura; Tateaki Naito; Masahiro Endo; Nobuyuki Yamamoto
Journal:  Int J Clin Oncol       Date:  2010-06-17       Impact factor: 3.402

4.  Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.

Authors:  Windy Dean-Colomb; Kenneth R Hess; Elliana Young; Terrie G Gornet; Beverly C Handy; Stacy L Moulder; Nuhad Ibrahim; Lajos Pusztai; Daniel Booser; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva
Journal:  Breast Cancer Res Treat       Date:  2012-12-15       Impact factor: 4.872

Review 5.  The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review.

Authors:  Winnie Sohn; Mary Ann Simiens; Kelly Jaeger; Shauna Hutton; Graham Jang
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

6.  Bone metastases in patients with small cell lung carcinoma: rate of development, early versus late onset, modality of treatment, and their impact on survival. A single-institution retrospective cohort study.

Authors:  Andriani Charpidou; Sofia Tsagouli; Ioannis Gkiozos; Dimitra Grapsa; Michalis Moutsos; Maria Kiagia; Konstantinos Syrigos
Journal:  Clin Exp Metastasis       Date:  2016-05-21       Impact factor: 5.150

7.  Bone integrity and bone metastases in breast cancer.

Authors:  Catherine Van Poznak; Cristina Nadal
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

8.  A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.

Authors:  Jianda Huang; Tongjie Gu; Jun Ying
Journal:  Int J Clin Oncol       Date:  2017-07-04       Impact factor: 3.402

9.  Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.

Authors:  Xinmin Zhao; Xiaofeng Xu; Qunling Zhang; Zhen Jia; Si Sun; Jian Zhang; Biyun Wang; Zhonghua Wang; Xichun Hu
Journal:  BMC Cancer       Date:  2011-09-22       Impact factor: 4.430

10.  Bone resorption predicts for skeletal complications in metastatic bone disease.

Authors:  J E Brown; C S Thomson; S P Ellis; S A Gutcher; O P Purohit; R E Coleman
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.